Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2019-11-01 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Change in Company Secretary/Compliance Officer
Regulatory Filings
2019-11-01 English
Change in Director(s)
Interim / Quarterly Report Classification · 95% confidence The document is a detailed disclosure from a company's board meeting held on November 1, 2019. It includes approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2019, along with limited review reports by statutory auditors. It also announces changes in company secretary and compliance officer, and appointment of an additional independent director. The document contains substantive financial data (quarterly and half-year financial results) and detailed management decisions. It is not merely an announcement of a report or a certification. The presence of unaudited financial results and limited review reports indicates this is an Interim / Quarterly Report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2019-11-01 English
Financial Result Updates
Regulatory Filings
2019-11-01 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed disclosure from a company's board meeting held on November 1, 2019. It includes approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2019, along with limited review reports by statutory auditors. It also announces changes in company secretary and compliance officer, and appointment of an additional independent director. The document contains actual financial data (unaudited financial results with figures for revenue, expenses, profit/loss, etc.) and detailed management decisions. It is not merely an announcement of a report or a certification. The presence of unaudited financial results for a quarter and half year period indicates this is an Interim / Quarterly Report (IR). H1 2020
2019-11-01 English
We are enclosing herewith Financial Results for the Second Quarter and half year ended 30th September, 2019
Regulatory Filings
2019-11-01 English
Outcome of Board Meeting
Regulatory Filings
2019-11-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.